Program Overview
This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will delve into a scientific update on Bruton tyrosine kinase inhibitors (BTKi) to improve outcomes for patients with multiple sclerosis (MS). The expert faculty, Dr. Benjamin Greenberg, will first review recent clinical trial data for BTK inhibitor therapeutics to treat patients with MS. Following, an analysis of strategies and imaging technologies to monitor disease progression and guide therapeutic selection to improve outcomes in patients with multiple sclerosis will be debated. Upon completion of this activity, learners will gain a better understanding of how to improve outcomes in patients with multiple sclerosis utilizing BTK inhibitors.
Target Audience
Neurologists, MS specialists, and physicians’ assistants who comprise the comprehensive MS care team, as well as other healthcare professionals involved in the management of patients with multiple sclerosis
Agenda
I. Clinical Data Review of BTK Inhibitor Therapeutics to Manage Patients with Multiple Sclerosis
II. Advances in Strategies and Imaging Technologies to Monitor Disease Progress and Guide Therapeutic Selection to Improve Outcomes in Patients with MS
Learning Objectives
- Analyze recent clinical trial data for BTK inhibitor therapeutics to treat patients with multiple sclerosis.
- Review strategies and imaging technologies to monitor disease progress and guide therapeutic selection to improve outcomes in patients with MS.
Faculty
Benjamin M. Greenberg, MD
Professor, Neurology
UT Southwestern
Dallas, TX
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Benjamin M. Greenberg, MD | Consultant/Advisor: Alexion; Cycle Pharma; EMD Serono; Genentech/Roche; Genzyme; Horizon Therapeutics; Immunovant; IQVIA; Novartis; Sandoz; Signant
Grant/Research Support: Anokion; Clene Nanomedicine; NIH; Regeneron |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Financial Support
This activity has been supported by an independent educational grant from Sanofi
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
